Overview of the mechanisms of action for new and future therapies in the management of inflammatory bowel disease. (IMAGE)

First Hospital of Jilin University

Overview of the mechanisms of action for new and future therapies in the management of inflammatory bowel disease.

Caption

Antitumour necrosis factor alpha (anti-TNFα) agents include infliximab, adalimumab, golimumab, AVX-470 and OPRX-106. Janus kinase (JAK) inhibitors: tofacitinib, filgotinib and upadacitinib. Cytokine inhibitors: ustekinumab, which targets interleukin (IL) 12, subunit p40/p35; risankizumab, mirikizumab, guselkumab and brazikumab target IL-23, subunit p40/p19. Sphingosine-1-phosphate (S1P) receptor modulators: amiselimod, ozanimod, etrasimod and fingolimod. Antiadhesion agents: vedolizumab, etrolizumab and ontamalimab. The microRNA-124 agent is obefazimod. * indicates the cells which phosphodiesterase (PDE) inhibitors such as apremilast act upon. Image created through the use of www.biorender.com. MAdCAM-1, mucosal addressin cell adhesion molecule 1; STAT, signal transducer and activator of transcription; T cell, T lymphocytes; TL1A, tumour-necrosis factor-like cytokine 1A; α4β7, alpha 4 beta 7.

Credit

By Dr Aditi Kumar and Dr Philip J Smith

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted.

License

CC BY-NC

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.